IL93432A - הידראזינים והידראזידים, קוניוגטים שלהם עם מקרומולקולות, וקוניוגטים כאלה המסומנים ביונים מתכתיים - Google Patents

הידראזינים והידראזידים, קוניוגטים שלהם עם מקרומולקולות, וקוניוגטים כאלה המסומנים ביונים מתכתיים

Info

Publication number
IL93432A
IL93432A IL9343290A IL9343290A IL93432A IL 93432 A IL93432 A IL 93432A IL 9343290 A IL9343290 A IL 9343290A IL 9343290 A IL9343290 A IL 9343290A IL 93432 A IL93432 A IL 93432A
Authority
IL
Israel
Prior art keywords
compound
group
conjugates
oxysuccinimidyl
hydrogen
Prior art date
Application number
IL9343290A
Other languages
English (en)
Original Assignee
Johnson Mathey Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johnson Mathey Inc filed Critical Johnson Mathey Inc
Publication of IL93432A publication Critical patent/IL93432A/he

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36—Oxygen or sulfur atoms
    • C07D207/40—2,5-Pyrrolidine-diones
    • C07D207/404—2,5-Pyrrolidine-diones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms, e.g. succinimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G01N33/534—Production of labelled immunochemicals with radioactive label

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Paints Or Removers (AREA)
  • Manufacture Of Metal Powder And Suspensions Thereof (AREA)
IL9343290A 1989-02-24 1990-02-19 הידראזינים והידראזידים, קוניוגטים שלהם עם מקרומולקולות, וקוניוגטים כאלה המסומנים ביונים מתכתיים IL93432A (he)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US31527089A 1989-02-24 1989-02-24

Publications (1)

Publication Number Publication Date
IL93432A true IL93432A (he) 1994-02-27

Family

ID=23223639

Family Applications (1)

Application Number Title Priority Date Filing Date
IL9343290A IL93432A (he) 1989-02-24 1990-02-19 הידראזינים והידראזידים, קוניוגטים שלהם עם מקרומולקולות, וקוניוגטים כאלה המסומנים ביונים מתכתיים

Country Status (18)

Country Link
EP (1) EP0384769B1 (he)
JP (1) JP3073997B2 (he)
KR (1) KR0142079B1 (he)
AT (1) ATE137219T1 (he)
AU (1) AU630668B2 (he)
CA (1) CA2010800C (he)
DE (1) DE69026637T2 (he)
DK (1) DK0384769T3 (he)
ES (1) ES2085890T3 (he)
FI (1) FI95907C (he)
GR (1) GR3019758T3 (he)
HU (1) HU207293B (he)
IE (1) IE74849B1 (he)
IL (1) IL93432A (he)
NO (1) NO178186C (he)
NZ (2) NZ239288A (he)
PT (1) PT93264B (he)
ZA (1) ZA901283B (he)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5792444A (en) * 1989-05-09 1998-08-11 The General Hospital Corporation Labeled chemotactic peptides to image focal sites of infection or inflammation
US6001979A (en) 1989-08-29 1999-12-14 Nycomed Amersham Plc Cores for technetium radiopharmaceuticals
US5589576A (en) * 1989-08-29 1996-12-31 Amersham International Plc Cores for technetium radiopharmaceuticals
US5296599A (en) * 1991-09-19 1994-03-22 Millipore Corporation Activated carbamates compounds
GB9209641D0 (en) * 1992-05-02 1992-06-17 Johnson Matthey Plc Improvements in radiolabelling
GB9223168D0 (en) * 1992-11-05 1992-12-16 Johnson Matthey Plc Improvements in molecule labelling
US5750088A (en) * 1993-03-30 1998-05-12 The Dupont Merck Pharmaceutical Company Stable hydrazones linked to a peptide moiety as reagents for the preparation of radiopharmaceuticals
ATE162524T1 (de) * 1993-07-19 1998-02-15 Resolution Pharm Inc Hydrazine mit einer n3s konfiguration als radionukleide chelatoren
US5753206A (en) 1995-06-07 1998-05-19 Immunomedics, Inc. Radiometal-binding analogues of luteinizing hormone releasing hormone
US6686461B1 (en) 2000-03-22 2004-02-03 Solulink Bioscience, Inc. Triphosphate oligonucleotide modification reagents and uses thereof
US7102024B1 (en) 2000-08-01 2006-09-05 Schwartz David A Functional biopolymer modification reagents and uses thereof
AU4769701A (en) 2000-03-22 2001-10-03 Solulink Inc Hydrazine-based and carbonyl-based bifunctional crosslinking reagents
US7723296B2 (en) 2001-01-18 2010-05-25 Genzyme Corporation Methods for introducing mannose-6-phosphate and other oligosaccharides onto glycoproteins and its application thereof
JP5137814B2 (ja) 2005-04-06 2013-02-06 ジェンザイム・コーポレーション 治療ターゲティングのための酸不安定リンカーを介するｐｅｇおよびポリシアルリソソーム酵素のコンジュゲート
CN101631794B (zh) 2007-01-18 2013-01-02 建新公司 包含氨基氧基基团的寡糖及其轭合物
LT2889043T (lt) 2008-12-16 2019-07-10 Genzyme Corporation Sintetiniai tarpiniai junginiai oligosacharido-baltymo konjugatų gamybai

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57181058A (en) * 1981-04-30 1982-11-08 Ikeda Mohandou:Kk Compound labeled with 99m technetium, and its preparation
US4861869A (en) * 1986-05-29 1989-08-29 Mallinckrodt, Inc. Coupling agents for joining radionuclide metal ions with biologically useful proteins
DE3728599A1 (de) * 1986-12-10 1988-06-23 Hoechst Ag Verfahren zur herstellung einer mit technetium-99m-markierten organspezifischen substanz
US5066490A (en) * 1988-06-01 1991-11-19 The United States Of America As Represented By The Secretary Of The Department Of Health & Human Services Protein crosslinking reagents cleavable within acidified intracellular vesicles

Also Published As

Publication number Publication date
HUT53600A (en) 1990-11-28
PT93264A (pt) 1990-08-31
IE74849B1 (en) 1997-08-13
DE69026637T2 (de) 1996-09-26
FI900948A0 (fi) 1990-02-23
FI95907C (fi) 1996-04-10
DK0384769T3 (da) 1996-05-13
JP3073997B2 (ja) 2000-08-07
DE69026637D1 (de) 1996-05-30
HU207293B (en) 1993-03-29
HU900970D0 (en) 1990-05-28
KR900012910A (ko) 1990-09-03
NO178186C (no) 1996-02-07
AU630668B2 (en) 1992-11-05
CA2010800C (en) 2001-01-16
IE900666L (en) 1990-08-24
EP0384769B1 (en) 1996-04-24
NZ232656A (en) 1992-04-28
NO178186B (no) 1995-10-30
EP0384769A2 (en) 1990-08-29
ES2085890T3 (es) 1996-06-16
CA2010800A1 (en) 1990-08-24
NO900838D0 (no) 1990-02-22
EP0384769A3 (en) 1991-11-27
PT93264B (pt) 1996-01-31
JPH0327356A (ja) 1991-02-05
ZA901283B (en) 1991-03-27
ATE137219T1 (de) 1996-05-15
KR0142079B1 (ko) 1998-06-01
FI95907B (fi) 1995-12-29
NO900838L (no) 1990-08-27
NZ239288A (en) 1992-04-28
AU5007490A (en) 1990-09-13
GR3019758T3 (en) 1996-07-31

Similar Documents

Publication Publication Date Title
US5753520A (en) Protein labelling
EP0384769B1 (en) Protein labelling
Schwartz et al. Preparation of hydrazino-modified proteins and their use for the synthesis of technetium-99m-protein conjugates
DE69408145T2 (de) Hydrazine mit einer n3s konfiguration als radionukleide chelatoren
KR100346795B1 (ko) 헤테로원자-포함 리간드 및 이의 금속 착화합물
EP0420934B1 (en) Bifunctional coupling agents and radionuclide labeled compositions prepared therefrom
JPH08502240A (ja) 二官能性キレート剤としての置換チオ尿素
FR2639947A1 (fr) Derives peptidiques
Mindt et al. A click approach to structurally diverse conjugates containing a central di‐1, 2, 3‐triazole metal chelate
US5021567A (en) 8-hydroxyquinoline chelating agents
JPH09503496A (ja) ヒドラジノ型ｎ▲下２▼ｓ▲下２▼キレート化剤
US5094950A (en) Diethylenetriamine pentaacetic acid derivatives
FI113044B (fi) 2-hydratsinopyridiinijohdannaisia
Banerjee et al. Design and synthesis of site directed maleimide bifunctional chelators for technetium and rhenium
JPH08504400A (ja) 放射性薬剤として使用する金属オキシムキレート
US5250702A (en) Diethylenetriamine pentaacetic acid derivatives
US5245026A (en) Metal containing 8-hydroxyquinoline chelating agents
US4870188A (en) Vinyl substituted radiohalogen conjugates for protein labeling
US5858327A (en) Hydrazino-type N2 S2 radionuclide chelating compounds
CA2141739A1 (en) Method for preparing a metal-radionuclide-labelled protein
JPH03501621A (ja) チオール反応性架橋試薬

Legal Events

Date Code Title Description
KB Patent renewed
KB Patent renewed
HP Change in proprietorship
KB Patent renewed
KB Patent renewed
EXP Patent expired